United Therapeutics Corporation (NASDAQ: UTHR) Stock Competitors & Peer Comparison
See UTHR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for UTHR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTHR | $541.70 | -5.19% | 23B | 19.38 | $27.95 | N/A |
| VRTX | $504.73 | -0.40% | 128.1B | 26.52 | $19.03 | N/A |
| REGN | $735.20 | +0.05% | 75.7B | 16.11 | $45.63 | +0.50% |
| MRNA | $190.01 | +0.57% | 75.4B | -23.31 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $919.21 | -1.79% | 57.2B | 33.14 | $27.73 | N/A |
| RVMDW | $11.41 | -1.64% | 45.2B | -1.31 | -$8.82 | N/A |
| RVMD | $206.64 | +0.36% | 43.9B | -23.43 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.07 | -0.20% | 38.3B | 63.04 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
UTHR vs VRTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, VRTX has a market cap of 128.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while VRTX trades at $504.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas VRTX's P/E ratio is 26.52. In terms of profitability, UTHR's ROE is +0.20%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, UTHR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
UTHR vs REGN Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while REGN trades at $735.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas REGN's P/E ratio is 16.11. In terms of profitability, UTHR's ROE is +0.20%, compared to REGN's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
UTHR vs MRNA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MRNA has a market cap of 75.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MRNA trades at $190.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MRNA's P/E ratio is -23.31. In terms of profitability, UTHR's ROE is +0.20%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, UTHR is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
UTHR vs VRNA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas VRNA's P/E ratio is -102.80. In terms of profitability, UTHR's ROE is +0.20%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, UTHR is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
UTHR vs ARGX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ARGX has a market cap of 57.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ARGX trades at $919.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ARGX's P/E ratio is 33.14. In terms of profitability, UTHR's ROE is +0.20%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, UTHR is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
UTHR vs RVMDW Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RVMDW has a market cap of 45.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RVMDW trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RVMDW's P/E ratio is -1.31. In terms of profitability, UTHR's ROE is +0.20%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, UTHR is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
UTHR vs RVMD Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RVMD has a market cap of 43.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RVMD trades at $206.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RVMD's P/E ratio is -23.43. In terms of profitability, UTHR's ROE is +0.20%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, UTHR is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
UTHR vs SGEN Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas SGEN's P/E ratio is -57.19. In terms of profitability, UTHR's ROE is +0.20%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, UTHR is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
UTHR vs ONC Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ONC trades at $358.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ONC's P/E ratio is 63.04. In terms of profitability, UTHR's ROE is +0.20%, compared to ONC's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
UTHR vs ALNY Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ALNY has a market cap of 29.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ALNY trades at $219.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ALNY's P/E ratio is 39.59. In terms of profitability, UTHR's ROE is +0.20%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, UTHR is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
UTHR vs ROIV Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ROIV has a market cap of 25.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ROIV trades at $35.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ROIV's P/E ratio is -33.98. In terms of profitability, UTHR's ROE is +0.20%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, UTHR is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
UTHR vs BNTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while BNTX trades at $96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas BNTX's P/E ratio is -12.57. In terms of profitability, UTHR's ROE is +0.20%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, UTHR is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
UTHR vs INSM Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, INSM has a market cap of 24.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while INSM trades at $111.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas INSM's P/E ratio is -27.04. In terms of profitability, UTHR's ROE is +0.20%, compared to INSM's ROE of -1.11%. Regarding short-term risk, UTHR is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
UTHR vs INCY Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, INCY has a market cap of 23.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while INCY trades at $115.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas INCY's P/E ratio is 15.50. In terms of profitability, UTHR's ROE is +0.20%, compared to INCY's ROE of +0.30%. Regarding short-term risk, UTHR is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check INCY's competition here
Genmab A/S (NASDAQ: GMAB)
UTHR vs GMAB Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while GMAB trades at $34.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas GMAB's P/E ratio is 26.19. In terms of profitability, UTHR's ROE is +0.20%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
UTHR vs BGNE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas BGNE's P/E ratio is -22.55. In terms of profitability, UTHR's ROE is +0.20%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, UTHR is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
UTHR vs DNA-WT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, UTHR's ROE is +0.20%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, UTHR is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
UTHR vs JAZZ Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while JAZZ trades at $235.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas JAZZ's P/E ratio is 8.79. In terms of profitability, UTHR's ROE is +0.20%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, UTHR is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
UTHR vs EXEL Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while EXEL trades at $58.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas EXEL's P/E ratio is 16.68. In terms of profitability, UTHR's ROE is +0.20%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, UTHR is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
UTHR vs NBIX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while NBIX trades at $143.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas NBIX's P/E ratio is 20.69. In terms of profitability, UTHR's ROE is +0.20%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, UTHR is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
UTHR vs ASND Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ASND trades at $227.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ASND's P/E ratio is -94.16. In terms of profitability, UTHR's ROE is +0.20%, compared to ASND's ROE of +1.90%. Regarding short-term risk, UTHR is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
UTHR vs SMMT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while SMMT trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas SMMT's P/E ratio is -14.96. In terms of profitability, UTHR's ROE is +0.20%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, UTHR is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
UTHR vs BBIO Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while BBIO trades at $67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas BBIO's P/E ratio is -17.98. In terms of profitability, UTHR's ROE is +0.20%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, UTHR is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BBIO's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
UTHR vs HALO Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while HALO trades at $109.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas HALO's P/E ratio is 19.95. In terms of profitability, UTHR's ROE is +0.20%, compared to HALO's ROE of +1.81%. Regarding short-term risk, UTHR is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
UTHR vs KRTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas KRTX's P/E ratio is -28.09. In terms of profitability, UTHR's ROE is +0.20%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, UTHR is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check KRTX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
UTHR vs TXG Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TXG has a market cap of 11.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TXG trades at $93.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TXG's P/E ratio is -158.47. In terms of profitability, UTHR's ROE is +0.20%, compared to TXG's ROE of -0.09%. Regarding short-term risk, UTHR is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
UTHR vs TWST Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TWST trades at $188.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TWST's P/E ratio is -84.99. In terms of profitability, UTHR's ROE is +0.20%, compared to TWST's ROE of -0.30%. Regarding short-term risk, UTHR is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
UTHR vs MDGL Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MDGL trades at $499.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MDGL's P/E ratio is -39.02. In terms of profitability, UTHR's ROE is +0.20%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, UTHR is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
UTHR vs TECH Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TECH's P/E ratio is 37.32. In terms of profitability, UTHR's ROE is +0.20%, compared to TECH's ROE of +0.09%. Regarding short-term risk, UTHR is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
UTHR vs RNAM Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RNAM's P/E ratio is -17.39. In terms of profitability, UTHR's ROE is +0.20%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, UTHR is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
UTHR vs BMRN Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while BMRN trades at $57.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas BMRN's P/E ratio is 27.49. In terms of profitability, UTHR's ROE is +0.20%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, UTHR is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
UTHR vs IBRX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, IBRX has a market cap of 10.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while IBRX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas IBRX's P/E ratio is -10.60. In terms of profitability, UTHR's ROE is +0.20%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, UTHR is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
UTHR vs RXDX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RXDX's P/E ratio is -56.47. In terms of profitability, UTHR's ROE is +0.20%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, UTHR is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
UTHR vs KRYS Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while KRYS trades at $322.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas KRYS's P/E ratio is 40.39. In terms of profitability, UTHR's ROE is +0.20%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, UTHR is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check KRYS's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
UTHR vs AXSM Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, AXSM has a market cap of 9.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while AXSM trades at $179.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas AXSM's P/E ratio is -46.80. In terms of profitability, UTHR's ROE is +0.20%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, UTHR is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check AXSM's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
UTHR vs NUVL Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas NUVL's P/E ratio is -21.79. In terms of profitability, UTHR's ROE is +0.20%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, UTHR is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check NUVL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
UTHR vs ARWR Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ARWR trades at $64.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ARWR's P/E ratio is -28.53. In terms of profitability, UTHR's ROE is +0.20%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, UTHR is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
UTHR vs PTGX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while PTGX trades at $140.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas PTGX's P/E ratio is 135.98. In terms of profitability, UTHR's ROE is +0.20%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, UTHR is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check PTGX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
UTHR vs CRNX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CRNX's P/E ratio is -16.86. In terms of profitability, UTHR's ROE is +0.20%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, UTHR is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CRNX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
UTHR vs KYMR Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while KYMR trades at $107.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas KYMR's P/E ratio is -33.56. In terms of profitability, UTHR's ROE is +0.20%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, UTHR is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
UTHR vs IMGN Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas IMGN's P/E ratio is -111.55. In terms of profitability, UTHR's ROE is +0.20%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, UTHR is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check IMGN's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
UTHR vs BPMC Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas BPMC's P/E ratio is -51.58. In terms of profitability, UTHR's ROE is +0.20%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, UTHR is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
UTHR vs APGE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas APGE's P/E ratio is -31.19. In terms of profitability, UTHR's ROE is +0.20%, compared to APGE's ROE of -0.30%. Regarding short-term risk, UTHR is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
UTHR vs TGTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TGTX trades at $54.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TGTX's P/E ratio is 19.67. In terms of profitability, UTHR's ROE is +0.20%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, UTHR is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TGTX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
UTHR vs PRAX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while PRAX trades at $295.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas PRAX's P/E ratio is -22.85. In terms of profitability, UTHR's ROE is +0.20%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, UTHR is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
UTHR vs CERE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CERE's P/E ratio is -16.47. In terms of profitability, UTHR's ROE is +0.20%, compared to CERE's ROE of -0.72%. Regarding short-term risk, UTHR is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
UTHR vs CYTK Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CYTK trades at $65.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CYTK's P/E ratio is -9.09. In terms of profitability, UTHR's ROE is +0.20%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, UTHR is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CYTK's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
UTHR vs PCVX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while PCVX trades at $56.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas PCVX's P/E ratio is -7.40. In terms of profitability, UTHR's ROE is +0.20%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, UTHR is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
UTHR vs SYRE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while SYRE trades at $93.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas SYRE's P/E ratio is -47.79. In terms of profitability, UTHR's ROE is +0.20%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, UTHR is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check SYRE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
UTHR vs CAI Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CAI has a market cap of 8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CAI trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CAI's P/E ratio is 79.52. In terms of profitability, UTHR's ROE is +0.20%, compared to CAI's ROE of +0.19%. Regarding short-term risk, UTHR is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CAI's competition here
Metsera, Inc. (NASDAQ: MTSR)
UTHR vs MTSR Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MTSR's P/E ratio is -23.58. In terms of profitability, UTHR's ROE is +0.20%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, UTHR is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
UTHR vs IONS Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while IONS trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas IONS's P/E ratio is -13.31. In terms of profitability, UTHR's ROE is +0.20%, compared to IONS's ROE of -1.11%. Regarding short-term risk, UTHR is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
UTHR vs IMVT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while IMVT trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas IMVT's P/E ratio is -11.92. In terms of profitability, UTHR's ROE is +0.20%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, UTHR is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
UTHR vs MRUS Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MRUS's P/E ratio is -17.05. In terms of profitability, UTHR's ROE is +0.20%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, UTHR is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MRUS's competition here
Abivax S.A. (NASDAQ: ABVX)
UTHR vs ABVX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ABVX has a market cap of 6.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ABVX trades at $92.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ABVX's P/E ratio is -15.22. In terms of profitability, UTHR's ROE is +0.20%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, UTHR is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ABVX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
UTHR vs ACLX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ACLX's P/E ratio is -28.27. In terms of profitability, UTHR's ROE is +0.20%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, UTHR is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
UTHR vs RETA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RETA's P/E ratio is -66.29. In terms of profitability, UTHR's ROE is +0.20%, compared to RETA's ROE of +0.47%. Regarding short-term risk, UTHR is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
UTHR vs BLTE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while BLTE trades at $159.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas BLTE's P/E ratio is -85.33. In terms of profitability, UTHR's ROE is +0.20%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, UTHR is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
UTHR vs RYTM Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RYTM trades at $92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RYTM's P/E ratio is -29.85. In terms of profitability, UTHR's ROE is +0.20%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, UTHR is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RYTM's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
UTHR vs IOVA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, IOVA has a market cap of 6.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while IOVA trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas IOVA's P/E ratio is -19.47. In terms of profitability, UTHR's ROE is +0.20%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, UTHR is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check IOVA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
UTHR vs CNTA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CNTA's P/E ratio is -22.63. In terms of profitability, UTHR's ROE is +0.20%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, UTHR is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
UTHR vs LGND Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while LGND trades at $302.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas LGND's P/E ratio is 33.26. In terms of profitability, UTHR's ROE is +0.20%, compared to LGND's ROE of +0.20%. Regarding short-term risk, UTHR is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
UTHR vs CGON Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CGON trades at $67.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CGON's P/E ratio is -25.05. In terms of profitability, UTHR's ROE is +0.20%, compared to CGON's ROE of -0.25%. Regarding short-term risk, UTHR is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CGON's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
UTHR vs KOD Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while KOD trades at $94.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas KOD's P/E ratio is -22.65. In terms of profitability, UTHR's ROE is +0.20%, compared to KOD's ROE of -2.73%. Regarding short-term risk, UTHR is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
UTHR vs CDTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CDTX's P/E ratio is -19.77. In terms of profitability, UTHR's ROE is +0.20%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, UTHR is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CDTX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
UTHR vs SRRK Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while SRRK trades at $46.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas SRRK's P/E ratio is -13.57. In terms of profitability, UTHR's ROE is +0.20%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, UTHR is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
UTHR vs ABCM Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, UTHR's ROE is +0.20%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, UTHR is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
UTHR vs ISEE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ISEE's P/E ratio is -22.44. In terms of profitability, UTHR's ROE is +0.20%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, UTHR is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
UTHR vs CRSP Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CRSP trades at $55.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CRSP's P/E ratio is -11.64. In terms of profitability, UTHR's ROE is +0.20%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, UTHR is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CRSP's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
UTHR vs COGT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while COGT trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas COGT's P/E ratio is -14.70. In terms of profitability, UTHR's ROE is +0.20%, compared to COGT's ROE of -0.73%. Regarding short-term risk, UTHR is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
UTHR vs PTCT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while PTCT trades at $63.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas PTCT's P/E ratio is -27.24. In terms of profitability, UTHR's ROE is +0.20%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, UTHR is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
UTHR vs TVTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TVTX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TVTX's P/E ratio is -126.51. In terms of profitability, UTHR's ROE is +0.20%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, UTHR is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
UTHR vs APLS Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas APLS's P/E ratio is 38.35. In terms of profitability, UTHR's ROE is +0.20%, compared to APLS's ROE of +0.40%. Regarding short-term risk, UTHR is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
UTHR vs ERAS Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ERAS trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ERAS's P/E ratio is -15.85. In terms of profitability, UTHR's ROE is +0.20%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, UTHR is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
UTHR vs ORKA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ORKA trades at $84.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ORKA's P/E ratio is -43.57. In terms of profitability, UTHR's ROE is +0.20%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, UTHR is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ORKA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
UTHR vs MIRM Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MIRM trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MIRM's P/E ratio is -5.70. In terms of profitability, UTHR's ROE is +0.20%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, UTHR is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
UTHR vs DFTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while DFTX trades at $37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas DFTX's P/E ratio is N/A. In terms of profitability, UTHR's ROE is +0.20%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, UTHR is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check DFTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
UTHR vs DNTH Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while DNTH trades at $88.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas DNTH's P/E ratio is -21.26. In terms of profitability, UTHR's ROE is +0.20%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, UTHR is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check DNTH's competition here
Veradermics, Incorporated (NYSE: MANE)
UTHR vs MANE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MANE trades at $116.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MANE's P/E ratio is -37.17. In terms of profitability, UTHR's ROE is +0.20%, compared to MANE's ROE of -0.38%. Regarding short-term risk, UTHR is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
UTHR vs TERN Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TERN's P/E ratio is -51.41. In terms of profitability, UTHR's ROE is +0.20%, compared to TERN's ROE of -0.20%. Regarding short-term risk, UTHR is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
UTHR vs FOLD Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas FOLD's P/E ratio is -161.00. In terms of profitability, UTHR's ROE is +0.20%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, UTHR is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check FOLD's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
UTHR vs ADPT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ADPT trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ADPT's P/E ratio is -69.15. In terms of profitability, UTHR's ROE is +0.20%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, UTHR is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ADPT's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
UTHR vs AKRO Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas AKRO's P/E ratio is -14.57. In terms of profitability, UTHR's ROE is +0.20%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, UTHR is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
UTHR vs ALPN Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ALPN's P/E ratio is -101.52. In terms of profitability, UTHR's ROE is +0.20%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, UTHR is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
UTHR vs EWTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while EWTX trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas EWTX's P/E ratio is -22.38. In terms of profitability, UTHR's ROE is +0.20%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, UTHR is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check EWTX's competition here
Opthea Limited (NASDAQ: OPT)
UTHR vs OPT Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas OPT's P/E ratio is -1.52. In terms of profitability, UTHR's ROE is +0.20%, compared to OPT's ROE of +1.18%. Regarding short-term risk, UTHR is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
UTHR vs PRTC Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas PRTC's P/E ratio is -3.78. In terms of profitability, UTHR's ROE is +0.20%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, UTHR is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check PRTC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
UTHR vs ABCL Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while ABCL trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas ABCL's P/E ratio is -25.44. In terms of profitability, UTHR's ROE is +0.20%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, UTHR is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check ABCL's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
UTHR vs RLAY Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RLAY trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RLAY's P/E ratio is -12.08. In terms of profitability, UTHR's ROE is +0.20%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, UTHR is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
UTHR vs MRTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas MRTX's P/E ratio is -4.82. In terms of profitability, UTHR's ROE is +0.20%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, UTHR is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
UTHR vs CPRX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CPRX's P/E ratio is 17.49. In terms of profitability, UTHR's ROE is +0.20%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, UTHR is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CPRX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
UTHR vs TNGX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TNGX trades at $23.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TNGX's P/E ratio is -28.00. In terms of profitability, UTHR's ROE is +0.20%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, UTHR is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
UTHR vs RYZB Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas RYZB's P/E ratio is -57.86. In terms of profitability, UTHR's ROE is +0.20%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, UTHR is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
UTHR vs CBAY Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas CBAY's P/E ratio is -32.81. In terms of profitability, UTHR's ROE is +0.20%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, UTHR is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
UTHR vs XENE Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, XENE has a market cap of 3.7B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while XENE trades at $38.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas XENE's P/E ratio is -8.09. In terms of profitability, UTHR's ROE is +0.20%, compared to XENE's ROE of -0.44%. Regarding short-term risk, UTHR is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check XENE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
UTHR vs TLX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while TLX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas TLX's P/E ratio is 110.13. In terms of profitability, UTHR's ROE is +0.20%, compared to TLX's ROE of +0.07%. Regarding short-term risk, UTHR is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check TLX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
UTHR vs IDYA Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while IDYA trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas IDYA's P/E ratio is -19.26. In terms of profitability, UTHR's ROE is +0.20%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, UTHR is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check IDYA's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
UTHR vs SWTX Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas SWTX's P/E ratio is -13.78. In terms of profitability, UTHR's ROE is +0.20%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, UTHR is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for UTHR.Check SWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
UTHR vs PBLS Comparison October 2026
United Therapeutics Corporation (NASDAQ: UTHR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTHR stands at 23B. In comparison, PBLS has a market cap of 3.5B. Regarding current trading prices, UTHR is priced at $541.70 on the NASDAQ, while PBLS trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTHR currently has a P/E ratio of 19.38, whereas PBLS's P/E ratio is -16.11. In terms of profitability, UTHR's ROE is +0.20%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, UTHR is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for UTHR.Check PBLS's competition here